You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 141 No. 3, March 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (7)
 •Contact me when this article is cited
 Related Content
 •Related letter
 •Similar articles in this journal
 Topic Collections
 •Dermatology
 •Melanoma
 •Surgical Oncology
 •Alert me on articles by topic

Futility of Fluorodeoxyglucose F 18 Positron Emission Tomography in Initial Evaluation of Patients With T2 to T4 Melanoma

Paige B. Clark, MD; Victoria Soo, BS; Jonathan Kraas, MD; Perry Shen, MD; Edward A. Levine, MD

Arch Surg. 2006;141:284-288.

Background  Evaluation of newly diagnosed patients with melanoma for metastasis is requisite to treatment planning. The reported diagnostic yield of whole-body conventional radiological imaging in initial staging of patients with melanoma is low. However, the diagnostic yield of positron emission tomography (PET) for distant metastases is unclear.

Hypothesis  There is no utility of PET as part of a routine metastatic survey in patients with T2 to T4 melanoma.

Design  Retrospective review of a cohort study between December 1998 and July 2004.

Setting  University hospital tertiary care center.

Patients and Methods  There were 64 patients with T2 to T4 melanomas who underwent PET for detection of occult metastases at our institution. All patients underwent surgical excision of the primary lesion and sentinel lymph node dissection. Data included were pathologic findings of the primary lesion and sentinel lymph nodes, laboratory data, and radiological reports. None of the patients had clinically suspected regional or distant metastases prior to PET. The diagnostic yield of PET was evaluated through retrospective analysis. Positive scans were then correlated for accuracy with follow-up imaging, biopsy, and clinical information when available.

Results  Positron emission tomography did not reveal occult distant metastases in any of the patients. Positron emission tomographic scans showed no abnormalities in 94% of these patients. In 2 patients (3%), false-positive findings were reported on PET (muscular activity and intranodal melanocytic nevocellular inclusion). Further, PET was not useful in predicting regional lymph node metastases. Nineteen of 64 patients had positive sentinel lymph nodes, and only 2 (11%) were identified on PET. Overall, PET did not change clinical management in any of the patients.

Conclusions  This study suggests no utility for PET in the detection of occult metastases in patients at initial diagnosis of melanoma. Omission of PET imaging from preoperative evaluations for patients with melanoma is recommended.


Author Affiliations: Department of Nuclear Medicine (Drs Clark and Kraas), Surgical Oncology Service (Drs Shen, Levine, and Ms Soo), Wake Forest University Health Sciences, Winston-Salem, NC.


RELATED LETTER

Futility of Positron Emission Tomography and Other Modalities in the Initial Radiographic Screening of Patients With Melanoma
Edward P. Miranda
Arch Surg. 2006;141(10):1050.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Yield and Predictors of Radiologic Studies for Identifying Distant Metastases in Melanoma Patients with a Positive Sentinel Lymph Node Biopsy
Gold et al.
Ann. Surg. Oncol. 2007;14:2133-2140.
ABSTRACT | FULL TEXT  

Futility of Positron Emission Tomography and Other Modalities in the Initial Radiographic Screening of Patients With Melanoma
Miranda
Arch Surg 2006;141:1050-1050.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.